Damora Therapeutics Reports FY25 Results, Advances MutCALR Blood Disorder Pipeline with $257.6 Million in Cash

Damora Therapeutics reported FY25 results with a net loss of $209.8 million, compared to $21.4 million in the prior year, driven by costs tied to its 2025 acquisition of the mutCALR pipeline. The company has $535 million in cash and is advancing its mutCALR-targeted therapies, including DMR-001, DMR-002, and DMR-003, with IND/CTA filings expected in 2026 and 2027.